Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now OTC Markets OTCPK - Delayed Quote • USD Silence Therapeutics plc (SLNCF) Follow Compare 0.5000 -0.2600 (-34.21%) As of April 14 at 10:22:43 AM EDT. Market Open. Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for SLNCF 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: SLNCF View More All News Press Releases SEC Filings Silence Therapeutics plc (NASDAQ:SLN): When Will It Breakeven? Revenue Downgrade: Here's What Analysts Forecast For Silence Therapeutics plc (NASDAQ:SLN) Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know Silence Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025 Institutional owners may take dramatic actions as Silence Therapeutics plc's (NASDAQ:SLN) recent 14% drop adds to one-year losses Silence Therapeutics plc (SLN): Among the Oversold Global Stocks to Buy Right Now Insider Traders Lose UK£124k As Silence Therapeutics Drops Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting